August 02, 2012
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
FDA approves generic version of asthma medication
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA recently issued an approval to Watson Laboratories for a generic version of a drug designed to control and prevent asthma symptoms in children, according to a press release.
Budesonide inhalation suspension, the generic version of Pulmicort Respules (AstraZeneca), is intended for children aged 12 months to 8 years and will be available in dose ampules of 0.25 mg/2mL and 0.5 mg/2mL.
The company, a subsidiary of Watson Pharmaceuticals, is currently in patent litigation with AstraZeneca, but anticipates launching the drug later this year pending the results of a motion for a preliminary injunction.